Case Details
- Citation: [2022] SGHC 234
- Title: Medica Singapore Pte Ltd v Chabtini Elias Georges
- Court: High Court of the Republic of Singapore (General Division)
- Date of Decision: 28 September 2022
- Judge: Valerie Thean J
- Suit No: Suit No 56 of 2021
- Hearing Dates: 4–7 April, 9 May 2022, 18 July 2022
- Plaintiff/Applicant: Medica Singapore Pte Ltd (“Medica SG”)
- Defendant/Respondent: Chabtini Elias Georges (“Mr Chabtini”)
- Legal Area: Trusts — Express trusts (certainties; intention to create trust)
- Statutes Referenced: Not specified in the provided extract
- Cases Cited: [2022] SGHC 234 (as reflected in the metadata); Guy Neale and others v Nine Squares Pty Ltd [2015] 1 SLR 1097 (express trust principles)
- Judgment Length: 23 pages, 6,192 words
Summary
In Medica Singapore Pte Ltd v Chabtini Elias Georges [2022] SGHC 234, the High Court considered whether trade marks registered in the name of Medica Singapore Pte Ltd were held on an express trust for another entity, SRS International S.P.R.L (“SRSI”). The dispute arose from Mr Chabtini’s unilateral steps to transfer ownership of certain Singapore trade marks to EMA Aesthetics Limited (“EMA”), an Irish company in which he was a director. Medica SG alleged that the transfers were unauthorised and constituted breaches of Mr Chabtini’s fiduciary duties as a director.
The central issue was not whether Mr Chabtini acted improperly as a matter of corporate governance, but whether the trade marks were held by Medica SG on trust for SRSI. If an express trust existed, Mr Chabtini’s position was that he was dealing with property that ultimately belonged beneficially to SRSI (and later EMA, after EMA acquired SRSI’s rights). If no express trust existed, the marks belonged to Medica SG, and the transfer would be wrongful.
The court held that the requirements for an express trust—particularly certainty of intention—were not satisfied on the evidence. Accordingly, Medica SG was entitled to declarations and consequential relief. The court ordered Mr Chabtini to take steps to transfer the relevant SRS trade mark in Indonesia and Taiwan back to Medica SG and awarded damages limited to the costs Medica SG incurred in reversing the transfers it was able to recover.
What Were the Facts of This Case?
Medica SG is a Singapore-incorporated company engaged in the wholesale medical equipment and cosmetic products sector. At the time of the dispute, Mr Chabtini held 48% of Medica SG’s shares and was formerly one of its directors. Ms Virginia Seow (“Ms Seow”) held 52% of the shares and was Medica SG’s sole director at the relevant time. The corporate history is important because it frames the relationship between the parties and the control Mr Chabtini exercised over the group’s branding and intellectual property strategy.
Medica Group was originally founded in the United Arab Emirates by Mr Chabtini and Ms Tania Akl in the late 1990s to early 2000s. Medica SG was incorporated in 2002 as part of an international expansion plan. Initially, Mr Chabtini and Mr Namir Robert Akl (Ms Akl’s husband) were shareholders, with Mr Chabtini holding 60% and Mr Akl holding 40%. Later, Mr Akl transferred his shares to Ms Akl. Over time, Ms Seow became a shareholder in 2015 through gifts of shares from Ms Akl and Mr Chabtini, reflecting her contributions to the business. After the dispute arose, Ms Akl sold her shares to Ms Seow.
Within the broader group, two additional companies were incorporated: SRS International S.P.R.L (“SRSI”) in Belgium and SRS-Solution Pte Ltd (“SRSPL”) in Singapore. Both were owned by Mr Chabtini and Ms Akl in proportions of 60% and 40% respectively. In October 2018, Ms Akl transferred her shares in both companies to Mr Chabtini. This corporate structure became relevant because Mr Chabtini later asserted that SRSI was the beneficial owner of the trade marks at issue.
The trade marks were central to the dispute. The “SRS Mark” was registered in Singapore in Medica SG’s name on 9 June 2006 and renewed on 18 December 2015, remaining registered until June 2026 in class 3 for cosmetic and skincare-related goods. A second trade mark (“Second Mark”) was registered in Medica SG’s name on 30 November 2015, also in class 3, and was set to expire on 30 November 2025. The marks were associated with a “Skin Rejuvenation Solution” brand line conceived in the early period of Medica SG’s establishment and expansion.
In early 2019, EMA was incorporated in Ireland to merge various brands, including SRSI (but not Medica SG). Mr Chabtini was one of EMA’s directors. In June 2020, Mr Chabtini applied to IPOS to register a transfer of ownership of the Second Mark to EMA in Singapore. He also transferred the SRS Mark registered in Medica SG’s name in multiple jurisdictions (including Hong Kong, Indonesia, Thailand, and Taiwan) to EMA. As a result, IPOS wrote to Medica SG seeking confirmation whether it objected to the transfer. Ms Seow objected promptly by email, stating the transfer was unauthorised. Shortly thereafter, Mr Chabtini emailed IPOS instructing it to ignore the earlier email and asserting that he was owner and director of Medica SG and that IPOS should authorise the transfer.
Medica SG later discovered that registration transfers had been effected in several jurisdictions. It was able to reverse some transfers (notably Hong Kong and Thailand by the time of trial), but not all. The court record indicates that transfers in Indonesia and Taiwan remained problematic. Meanwhile, Medica SG removed Mr Chabtini as director at an extraordinary general meeting on 19 October 2020. Although Mr Chabtini initially disputed the validity of that meeting, he resigned five days later on 24 October 2020.
Medica SG commenced suit on 15 January 2021. It sought (among other relief) a declaration that it was the rightful owner of the marks, an order requiring Mr Chabtini to take steps to transfer the SRS Mark in certain jurisdictions back to Medica SG, damages for wrongful transfer, and damages for loss of profits. Mr Chabtini counterclaimed for outstanding salary and other debts. Shortly before trial, Medica SG admitted the counterclaim and paid $49,000 into court.
At trial, Medica SG’s case narrowed. It abandoned a prayer for a declaration of ownership in the broader sense on the first day of trial because Mr Chabtini’s defence was that SRSI was the beneficial owner and neither SRSI nor EMA was joined as a party. Further, Medica SG only pursued return of the SRS Mark in Indonesia and Taiwan because it had already reversed transfers in Hong Kong and Thailand. It also did not seek a remedy in respect of the Second Mark because IPOS had not effected the transfer in light of Medica SG’s protest. Ultimately, the remaining relief was damages of $5,850.90 (costs incurred in reversing transfers Medica SG could reverse) and an order requiring Mr Chabtini to take steps to transfer the SRS Mark in Indonesia and Taiwan back to Medica SG.
What Were the Key Legal Issues?
The sole issue for determination was whether the SRS Mark was held by Medica SG on an express trust for SRSI. This framed the entire dispute: if Medica SG held the mark beneficially for itself, Mr Chabtini’s transfer to EMA would be wrongful and would constitute a breach of his fiduciary duties as a director. Conversely, if Medica SG held the mark on trust for SRSI, then Mr Chabtini’s position was that he was acting consistently with the beneficial ownership structure, particularly after EMA acquired SRSI’s rights.
Accordingly, the court had to apply the established doctrine governing express trusts. The requirements include certainty of intention, certainty of subject matter, and certainty of objects. While the principles were not in dispute, the evidential question was whether the parties’ words or conduct demonstrated an intention to create a trust at the time the mark was registered in Medica SG’s name.
In addition, the case implicitly required the court to consider how to treat internal understandings or informal arrangements within a corporate group. Mr Chabtini’s defence relied on an alleged understanding that, because of challenges registering the mark in SRSI’s name at the time of registration in 2006, the mark was to be registered in Medica SG’s name “instead” and held by Medica SG “on behalf of SRSI.” The legal issue was whether such an understanding met the threshold for an express trust rather than merely reflecting a commercial arrangement, expectation, or administrative convenience.
How Did the Court Analyse the Issues?
The court began by restating the governing principles for express trusts. In Guy Neale and others v Nine Squares Pty Ltd [2015] 1 SLR 1097, the Court of Appeal held that an express trust is created by the actual intention of the settlor, as expressed by the use of the word “trust” in a relevant instrument or inferred from the settlor’s words or conduct. The court emphasised that three certainties must be present: certainty of intention, certainty of subject matter, and certainty of objects.
Although the extract provided does not reproduce the full analysis, the court’s approach can be understood from the way the dispute was narrowed to the express trust question and from the factual contest over the alleged “on behalf of” arrangement. The court treated the existence of an express trust as a matter requiring clear evidence of intention. In trust law, the intention to create a trust cannot be assumed merely because one party would benefit from a trust-like outcome. The court therefore examined whether there was sufficient evidence that Medica SG was intended to hold the marks on trust for SRSI, rather than holding them for itself subject to some informal or later-to-be-formalised arrangement.
Mr Chabtini’s evidence was that the “Skin Rejuvenation Solution” brand and trade mark were created by him and his team in the 2000s. He asserted that, at the time of registration in 2006, there were challenges registering the mark in SRSI’s name. He claimed that it was “understood and agreed” between him and Ms Akl that the mark would be registered in Medica SG’s name instead, and held by Medica SG on behalf of SRSI. This was the factual foundation for his position that Medica SG was not the beneficial owner.
The court’s reasoning turned on the certainty of intention. In express trust cases, certainty of intention requires that the alleged settlor’s intention to create a trust is sufficiently clear. The court would have been alert to the risk that the evidence amounted to a retrospective justification for corporate actions rather than a contemporaneous intention to create trust obligations. Where the evidence is limited to broad statements about ownership, benefit, or internal understandings, the court may find that the legal threshold for an express trust is not met.
In this case, the court ultimately found that the requirements for an express trust were not satisfied. The consequence was that Medica SG was the beneficial owner of the SRS Mark. Therefore, Mr Chabtini’s transfer of the mark to EMA—without authorisation from Medica SG—was wrongful. The court also tied this to Mr Chabtini’s fiduciary duties as a director. Directors owe duties to act in the best interests of the company and not to appropriate company property or deal with it in a manner inconsistent with the company’s rights. If the marks belonged beneficially to Medica SG, Mr Chabtini could not justify the transfer by reference to an alleged trust arrangement that did not meet the legal requirements.
Finally, the court’s analysis reflected the procedural narrowing of the claim. Because SRSI and EMA were not joined as parties, Medica SG abandoned certain prayers. The court therefore limited relief to what Medica SG could properly obtain against Mr Chabtini: damages for costs incurred in reversing transfers and an order requiring steps to transfer the remaining SRS Mark registrations in Indonesia and Taiwan back to Medica SG.
What Was the Outcome?
The court granted Medica SG the remaining remedies it pursued. It ordered Mr Chabtini to take steps to transfer the SRS Mark in Indonesia and Taiwan to Medica SG. The court also awarded damages of $5,850.90, representing the costs Medica SG incurred in reversing the transfers it was able to recover.
Interest was awarded at 5.33% from the date of the writ. Mr Chabtini appealed, but the High Court’s decision stands as the operative determination of the express trust issue and the consequent finding that Medica SG was the rightful beneficial owner of the SRS Mark.
Why Does This Case Matter?
This decision is significant for practitioners dealing with intellectual property held within corporate groups and for those advising on the legal consequences of informal arrangements. The case illustrates that courts will not readily infer an express trust from commercial context or internal understandings. Even where there is a plausible narrative that one entity “should” be the beneficial owner, the legal requirements—especially certainty of intention—must be met with evidence capable of supporting the creation of a trust.
For directors and corporate officers, the case also underscores fiduciary risk when dealing with company assets. If a director purports to transfer intellectual property registered in the company’s name, the director must ensure that the company’s beneficial ownership is properly understood and that any trust or nominee arrangement is legally established. Otherwise, the director may face liability for wrongful transfer and related costs, and may be ordered to take steps to reverse or rectify the transactions.
From a litigation strategy perspective, the case also demonstrates the importance of proper party joinder when beneficial ownership and trust structures are asserted. Medica SG’s abandonment of certain prayers due to the non-joinder of SRSI and EMA shows that trust disputes can become procedurally constrained if the entities whose rights are implicated are not before the court.
Legislation Referenced
- Not specified in the provided extract.
Cases Cited
Source Documents
This article analyses [2022] SGHC 234 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.